Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology - PubMed (original) (raw)

Review

Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

Cem Akin. J Mol Diagn. 2006 Sep.

Abstract

Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Multifocal clusters of mast cells in a bone marrow biopsy visualized by immunohistochemical staining for tryptase satisfy the World Health Organization major diagnostic criterion in this patient with indolent systemic mastocytosis.

Figure 2

Figure 2

Mast cells in bone marrow aspirate smears show aberrant morphological features such as spindling and hypogranulation (A), as compared to normal mast cells with a round and centrally located nucleus and dense cytoplasmic granulation (B).

Figure 3

Figure 3

C-_kit_mutations in mastocytosis. EC, extracellular (ligand binding); TM, transmembrane; JM, juxtamembrane; TK, tyrosine kinase domain. The most common mutation, D816V, is shown boxed.

Figure 4

Figure 4

Demonstration of D816V c-_kit_mutation by RFLP (A) and capillary sequencing (B). A:_Hin_fI digestion of the RT-PCR product from HMC1.2 cell line (lane 1, positive control) and patient samples in lanes 4 and 6 show the presence of an additional band (arrow) as a result of creating a new restriction site by A>T nucleotide change in c-_kit_codon 816. Lanes 2, 3, and 5 show wild-type pattern codon 816. B: Demonstration of the heterozygous A>T nucleotide change in cDNA position 2468 (corresponding to amino acid change D816V) by direct capillary sequencing (right), and its comparison to the wild-type sequence (left).

Similar articles

Cited by

References

    1. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–432. - PubMed
    1. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–690. - PubMed
    1. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519–528. - PubMed
    1. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:695–717. - PubMed
    1. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965–972. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources